Lucia Viganò

3.6k total citations · 1 hit paper
38 papers, 2.9k citations indexed

About

Lucia Viganò is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lucia Viganò has authored 38 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 12 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lucia Viganò's work include Cancer Treatment and Pharmacology (18 papers), HER2/EGFR in Cancer Research (8 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Lucia Viganò is often cited by papers focused on Cancer Treatment and Pharmacology (18 papers), HER2/EGFR in Cancer Research (8 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Lucia Viganò collaborates with scholars based in Italy, Switzerland and United States. Lucia Viganò's co-authors include Luca Gianni, Alberta Locatelli, Giuseppe Capri, Gianni Bonadonna, Merrill J. Egorin, Christine M. Kearns, Francesca Sisto, Arianna Bonomi, Giulio Alessandri and Emilio Ciusani and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Lucia Viganò

38 papers receiving 2.8k citations

Hit Papers

Paclitaxel is incorporated by mesenchymal stromal cells a... 2014 2026 2018 2022 2014 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery
    2014 746 citations Valentina Coccè, Arianna Bonomi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lucia Viganò Italy 23 1.4k 1.3k 695 296 249 38 2.9k
Alberta Locatelli Italy 17 846 0.6× 1.1k 0.8× 648 0.9× 201 0.7× 205 0.8× 31 2.0k
Gerrit Jan Schuurhuis Netherlands 38 1.4k 1.0× 2.0k 1.5× 637 0.9× 207 0.7× 694 2.8× 114 4.7k
Henk J. Broxterman Netherlands 26 1.3k 0.9× 1.4k 1.1× 470 0.7× 379 1.3× 99 0.4× 51 2.8k
Robert J. Belt United States 20 1.5k 1.1× 789 0.6× 386 0.6× 459 1.6× 190 0.8× 59 2.6k
Heiko van der Kuip Germany 30 1.3k 0.9× 1.0k 0.8× 298 0.4× 212 0.7× 326 1.3× 60 2.8k
Denice Tsao‐Wei United States 33 2.1k 1.5× 1.9k 1.4× 716 1.0× 919 3.1× 202 0.8× 116 4.7k
Manon Huizing Belgium 29 2.2k 1.5× 664 0.5× 349 0.5× 457 1.5× 118 0.5× 98 3.0k
John Sarantopoulos United States 28 1.3k 0.9× 1.6k 1.2× 382 0.5× 528 1.8× 238 1.0× 143 3.2k
Lawrence Panasci Canada 35 2.0k 1.4× 1.9k 1.4× 1.0k 1.5× 813 2.7× 431 1.7× 113 4.1k
Giulio Francia United States 31 1.5k 1.1× 1.5k 1.1× 849 1.2× 540 1.8× 179 0.7× 69 3.2k

Countries citing papers authored by Lucia Viganò

Since Specialization
Citations

This map shows the geographic impact of Lucia Viganò's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucia Viganò with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucia Viganò more than expected).

Fields of papers citing papers by Lucia Viganò

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucia Viganò. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucia Viganò. The network helps show where Lucia Viganò may publish in the future.

Co-authorship network of co-authors of Lucia Viganò

This figure shows the co-authorship network connecting the top 25 collaborators of Lucia Viganò. A scholar is included among the top collaborators of Lucia Viganò based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucia Viganò. Lucia Viganò is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Perego, Gianluca, et al.. (2022). Stability of a standardized preparation of methotrexate, cytarabine, and methylprednisolone hemisuccinate for intrathecal use. Journal of Oncology Pharmacy Practice. 32(2). 272–277. 1 indexed citations
2.
Callari, Maurizio, Matteo Dugo, Barbara Galbardi, et al.. (2022). Abstract PD10-09: Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment. Cancer Research. 82(4_Supplement). PD10–9. 2 indexed citations
3.
Bianchini, Giampaolo, Matteo Dugo, Balázs Győrffy, et al.. (2021). ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.. Journal of Clinical Oncology. 39(15_suppl). 555–555. 1 indexed citations
4.
Quartino, Angelica, Hanbin Li, Jin Y. Jin, et al.. (2017). Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer. Cancer Chemotherapy and Pharmacology. 79(2). 353–361. 17 indexed citations
5.
Conte, Gianluca Del, Cristiana Sessa, Roger von Moos, et al.. (2014). Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. British Journal of Cancer. 111(4). 651–659. 88 indexed citations
6.
Villa, Raffaella, Barbara Cerroni, Lucia Viganò, et al.. (2013). Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells. Colloids and Surfaces B Biointerfaces. 110. 434–442. 45 indexed citations
7.
Bergh, Jonas, Gabriella Mariani, Fátima Cardoso, et al.. (2012). Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. The Breast. 21(4). 507–513. 21 indexed citations
8.
Pessina, Augusto, Arianna Bonomi, Valentina Coccè, et al.. (2011). Mesenchymal Stromal Cells Primed with Paclitaxel Provide a New Approach for Cancer Therapy. PLoS ONE. 6(12). e28321–e28321. 143 indexed citations
9.
Cresta, Sara, Cristiana Sessa, Carlo V. Catapano, et al.. (2008). Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. European Journal of Cancer. 44(13). 1829–1834. 28 indexed citations
10.
Balottin, Umberto, Giorgio Rossi, Lucia Viganò, et al.. (2008). The Rorschach test and Gilles de la Tourette’s syndrome: A pilot case–control study. Brain and Development. 31(9). 657–665. 9 indexed citations
11.
Sessa, Cristiana, Antonella Perotti, Cristina Noberasco, et al.. (2008). Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. European Journal of Cancer. 45(7). 1153–1161. 41 indexed citations
12.
Perotti, Antonella, Lucia Viganò, Elisa Gallerani, et al.. (2006). Phase Ib pharmacokinetic (PK) and pharmacodynamic (PD) study to define the optimal dose for combining the mTOR inhibitor AP23573 with capecitabine (CAPE). Journal of Clinical Oncology. 24(18_suppl). 3065–3065. 8 indexed citations
13.
Henningsson, Anja, Sharon Marsh, Walter J. Loos, et al.. (2005). Association ofCYP2C8, CYP3A4, CYP3A5, andABCB1Polymorphisms with the Pharmacokinetics of Paclitaxel. Clinical Cancer Research. 11(22). 8097–8104. 151 indexed citations
14.
Sessa, Cristiana, Antonella Perotti, Emanuela Salvatorelli, et al.. (2004). Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. European Journal of Cancer. 40(4). 563–570. 9 indexed citations
15.
Bianchi, Giulia, W. Eiermann, Giordano Vitali, et al.. (2003). Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.. PubMed. 9(16 Pt 1). 5944–51. 41 indexed citations
16.
Hawkins, Philip N., C. Aprile, Giuseppe Capri, et al.. (1998). Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging. 25(7). 701–708. 36 indexed citations
17.
Gianni, Luca, Lucia Viganò, Alberta Locatelli, et al.. (1997). Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.. Journal of Clinical Oncology. 15(5). 1906–1915. 236 indexed citations
18.
19.
Gianni, Luca, Lucia Viganò, Antonella Surbone, et al.. (1990). Pharmacology and Clinical Toxicity of 4'-Iodo-4'-deoxydoxorubicin: An Example of Successful Application of Pharmacokinetics to Dose Escalation in Phase I Trials. JNCI Journal of the National Cancer Institute. 82(6). 469–477. 54 indexed citations
20.
Gianni, Luca, et al.. (1988). Role of Daunosamine and Hydroxyacetyl Side Chain in Reaction With Iron and Lipid Peroxidation by Anthracyclines. JNCI Journal of the National Cancer Institute. 80(14). 1104–1111. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alberta Locatelli Breakdown of academic impact, for papers by Gerrit Jan Schuurhuis Breakdown of academic impact, for papers by Henk J. Broxterman Breakdown of academic impact, for papers by Robert J. Belt Breakdown of academic impact, for papers by Heiko van der Kuip Breakdown of academic impact, for papers by Denice Tsao‐Wei Breakdown of academic impact, for papers by Manon Huizing Breakdown of academic impact, for papers by John Sarantopoulos Breakdown of academic impact, for papers by Lawrence Panasci Breakdown of academic impact, for papers by Giulio Francia
Rankless by CCL
2026